Stockreport

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Matinas Biopharma Holdings, Inc.  (MTNB) 
NASDAQ:AMEX Investor Relations: ir.matinasbiopharma.com
PDF Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight l [Read more]